Magneto Thrombectomy Solutions
Thrombectomy Solutions
Startup Seed Health Tech & Life Sciences Est. 2016
Total Raised
$1.85M
Seed
Last Round
Undisclosed
5 rounds
Investors
1
1 public
Team
5
1-10 employees
Confidence
98/100
News
1
articles
Patents
1
About
Magneto is developing innovative thrombectomy solutions for the removal of blood clots in the vascular system. The Magneto catheters use electric fields to create an attraction with the target clot. When voltage is applied, the negatively charged ions of the clot are bonded to the active positive electrode of the catheter, creating a strong magnetic type of grip. This allows for clot removal without damaging the endoluminal surface of the vessel while lessening the chance of distal embolization. The fibrin content of a blood clot possesses high charge electrical density enabling strong adherence. Magneto's technology has been proven to be effective for all clot types - from acute- soft, red, Red Blood Cell-rich clots to chronic- firm, white, fibrin-rich clots. In-vitro tests have shown success in addressing a wide range of clot types with this proprietary technology. The eTrieve™ PE kit is custom designed for the pulmonary arteries. Using Magneto's large bore aspiration catheter, together with the eTrieve™ Catheter with its proprietary electric attachment technology, the system can remove both proximal and distal emboli with minimal artery interaction and less fragmentation. The company has demonstrated the safety and efficacy of its eTrieve PE Kit with its successful first-in-human (FIH) study. The results showed a significant reduction in right ventricular to left ventricular diameter (RV/LV) ratio and alleviation of symptoms associated with PE.
Classification
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Core Technology
Semiconductors & Electronics
Target Customer
Healthcare & Life SciencesHealthcareProviders
Business Model
B2B
Tags
catheterssurgerymedical-devicesneurosciencebioconvergence
Funding & Events
Oct 2024
SAFE $500K
Peregrine Ventures
Mar 2025
Non-equity Undisclosed
European Union’s EIC Fund (Lead)
Mar 2024
Undisclosed Round Undisclosed
Peregrine Ventures
Jun 2019
Seed Undisclosed
(Lead)
Jan 2023
Undisclosed Round $1.35M
Peregrine Ventures
News (1)
May 10, 2022 · www.prnewswire.com
growth-positive
Magneto Thrombectomy Solutions Announces Successful First-in-Human Results for Treatment of Pulmonary Embolism (PE)
InvestmentExpand
Details
Product Stage
Clinical Trial
Employees
1-10
Exact Count
6
District
Center District
Founded
2016
Registrar
515456317
Locations
Yehonatan Netanyahu Street 6, Or Yehuda, Israel
Links
Website
LinkedIn
Admin
Last Update
Aug 5, 2025
Verified by
Jenny Sotnik-Talisman
Claimed
Yes
Missing
markets
Team (5)
Benny Dilmoney
CEO
Rafi Benary
CO-FOUNDER & CTO
Yuval Taff
Co-founder & CSO
Founder
Tami Abudi
VP Clinical & Regulatory Affairs
Assaf Torjman
R&D DIRECTOR
Internal
Created by
Jenny Sotnik-Talisman (genys30@yahoo.com)
Created
2017-02-13T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)